Research is underway to evaluate the role of SGLT2 inhibitors in obesity management, as they can induce weight loss through caloric loss via glucosuria and potential appetite reduction [25]. The gene discussed is SLC5A2; the disease is obesity due to melanocortin 4 receptor deficiency.